Breast cancer is a highly heterogeneous disease, molecularly defined by gene expression signatures and clinically classified by immunohistochemical tests for hormonal (estrogen and progesterone) and human epidermal growth factor receptor 2 (HER2), receptors which have prognostic value and are used for defining targeted therapies [2]. This evidence concerns the gene ERBB2 and breast carcinoma.